We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
-24.99%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$160M
AUM Growth
-$78.8M
Cap. Flow
-$21.6M
Cap. Flow %
-13.46%
Top 10 Hldgs %
42.9%
Holding
67
New
14
Increased
18
Reduced
12
Closed
14

Top Buys

Rank Stock Value
1
AGIO icon
Agios Pharmaceuticals
AGIO
+$4.49M
2
CMRX
Chimerix, Inc.
CMRX
+$4.41M
3
TVRD
Tvardi Therapeutics
TVRD
+$3.55M
4
IMMU
Immunomedics Inc
IMMU
+$2.33M
5
SAGE
Sage Therapeutics
SAGE
+$2.29M

Top Sells

Rank Stock Value
1
RLYP
RELYPSA INC COM
RLYP
+$6.24M
2
CEMP
Cempra, Inc.
CEMP
+$6.23M
3
TNXP icon
Tonix Pharmaceuticals
TNXP
+$4.33M
4
AVGR
Avinger, Inc. Common Stock
AVGR
+$4.32M
5
SUPN icon
Supernus Pharmaceuticals
SUPN
+$3.85M

Sector Composition

Rank Sector Weight
1 Healthcare 88.12%
2 Miscellaneous 11.88%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CLLS
51
Cellectis
CLLS
$358M
– –
-50,000
Closed -$1.55M
MGNX icon
52
MacroGenics
MGNX
$260M
– –
-35,000
Closed -$1.08M
NBIX icon
53
Neurocrine Biosciences
NBIX
$15.8B
– –
-55,000
Closed -$3.11M
SGMO
54
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
– –
-60,000
Closed -$548K
TNXP icon
55
Tonix Pharmaceuticals
TNXP
$233M
– –
0
– -$4.33M
AVGR
56
DELISTED
Avinger, Inc. Common Stock
AVGR
– –
-2
Closed -$4.32M
AGRX
57
DELISTED
Agile Therapeutics
AGRX
– –
-150
Closed -$2.93M
ALDR
58
DELISTED
Alder Biopharmaceuticals
ALDR
– –
-65,000
Closed -$2.15M
CEMP
59
DELISTED
Cempra, Inc.
CEMP
– –
-200,000
Closed -$6.23M
VTAE
60
DELISTED
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
– –
-58,500
Closed -$1.06M
RLYP
61
DELISTED
RELYPSA INC COM
RLYP
– –
-220,000
Closed -$6.24M
LJPC
62
DELISTED
La Jolla Pharmaceutical Company
LJPC
– –
-140,000
Closed -$3.78M
1 2
3

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q1 2016 Portfolio in Review

As of Q1 2016, Opaleye Management held 67 positions worth $160M, down 33% from $239M the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Opaleye Management withdrew a net $21.6M in Q1 2016, closing 14 positions and reducing 12 holdings. Its most notable exit was RELYPSA INC COM, an estimated $6.24M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, up from 88% a quarter earlier, followed by Miscellaneous.

Against the trend, Opaleye Management opened a new position in Agios Pharmaceuticals worth $4.26M.

  • Opaleye Management's largest Q1 2016 buy was Agios Pharmaceuticals: 105,000 shares worth $4.26M.
  • Opaleye Management added most to Tvardi Therapeutics in Q1 2016, an estimated $3.55M increase.
  • Opaleye Management's biggest Q1 2016 reduction was Supernus Pharmaceuticals, cutting an estimated $3.85M.
  • Opaleye Management fully exited RELYPSA INC COM in Q1 2016, selling an estimated $6.24M.
  • Opaleye Management's ten largest holdings make up 43% of its $160M portfolio in Q1 2016.
  • Opaleye Management opened 14 new positions and closed 14 in Q1 2016.
  • Opaleye Management's portfolio value fell 33% quarter-over-quarter to $160M.

Based on Opaleye Management's 13F filing for Q1 2016, filed 16 May 2016.